Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 33, 08 March 2024
Open
Access | Article
The treatment of myopia and future development
* Author to whom correspondence should be addressed.
Abstract
Myopia is a relatively common disease at present, especially in the adolescent population is very high, and its prevalence increases with the passage of time, usually myopia will cause retinal detachment, glaucoma, etc., which may seriously lead to vision loss and blindness. Existing treatments include monocular lenses, contact lenses and refractive surgery, as well as the drugs atropine and pirrenzil. Studies have shown that most myopia treatments have little effect, are relatively short term, and have significant side effects. This article mainly summarizes the treatment methods of myopia, combined with the latest findings of clinical research, and put forward the possible future treatment methods.
Keywords
Therapy, Myopia, Treatment
References
1. Lin H W, Young M L, Pu C, Huang C Y, Lin K K, Lee J S and Hou C H 2023 Changes in anisometropia by age in children with hyperopia, myopia, and antimetropia. Scientific reports 13 13643.
2. Gwiazda J 2009 Treatment options for myopia. American Academy of Optometry 86 624–628.
3. Kaminski M M, Abudayyeh O O, Gootenberg J S, Zhang F and Collins J J 2021 CRISPR-based diagnostics. Nature biomedical engineering 5 643–656.
4. Huang Z, Fang J, Zhou M, Gong Z and Xiang T 2022. CRISPR-Cas13: a new technology for the rapid detection of pathogenic microorganisms. Frontiers in microbiology 13 1011399.
5. Cong L et al. 2013 Multiplex genome engineering using CRISPR/Cas systems. Science 339 819–823.
6. Joung J, Sander J 2013. TALENs: a widely applicable technology for targeted genome editing. Nat. Rev. Mol. Cell Biol. 14 49–55.
7. Cong L, Zhang F 2015 Genome engineering using CRISPR-Cas9 system. Methods Mol. Biol. 1239 197–217.
8. Kleinstiver B P, Pattanayak V, Prew M S, et al. 2016 The high-fidelity CRISPR-Cas9 nuclease had no detectable genome-wide off-target effects. The natural world 529 490–495.
9. Azangou-Khyavy M, Ghasemi M, Khanali J, Boroomand-Saboor M, Jamalkhah M, Soleimani M, et al. 2020 CRISPR/Cas: from tumor gene editing to T cell-based immunotherapy of cancer. Front. Immunol. 11 2062.
10. Ye L, Zhang F, et al. 2016 Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia. Proceedings of the National Academy of Sciences 113 10661–10665.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-323-4
- ISBN (Online)
- 978-1-83558-324-1
- Published Date
- 08 March 2024
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/33/20240423
- Copyright
- 08 March 2024
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited